Unsere Forschungstätigkeit
Das Freiburger Brustzentrum beteiligt sich aktiv an internationalen klinischen Studien sowie der Entwicklung von innovativen Medikamenten und neuen Technologien, um Krebs zu heilen. Die Ärztinnen und Ärzte können ihrer Patientin vorschlagen, im Rahmen der Forschung an einer klinischen Studie teilzunehmen.
Laufende Studien
SAKK 23/16 TAXIS
«Protocol SAKK 23/16 / IBCSG 57-18 / ABCSG-53. Tailored AXIllary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS).
A multicenter randomized phase III trial.»
SAKK 96/12
«Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial.»
RIB-ELLE NOVARTIS
«RIB-ELLE: A non-interventional study to assess the safety and efficacy of RIBociclib in combination with an aromatase inhibitor (letrozole, anastrozole, exemestane) or in combination with fulvestrant in the Swiss advanced breast cancer population.»
TOUCH IBCSG
«Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer. To reduce the use of Chemotherapy in postmenopausal patients with ER-positive and HER2-positive breast cancer: the TOUCH trial.»
POLAR IBCSG
«A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer.»
CASCADE
«Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland (2021 – ongoing)»
DECRESCENDO
«De-Escalation of adjuvant ChemotheRapy in HER2-positive, Estrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade.»